Advaxis, Inc. (ADXS, Financial), a company trading on the U.S. OTC market, experienced a significant stock price drop of 74.31%. The current trading price of ADXS stands at $0.027 per share with a trading volume of 5,499 shares, marking a negligible turnover rate of 0.01% with no price volatility recorded.
Financial reports reveal that Advaxis, Inc. has generated a revenue of $9,000, while incurring a net loss of $8.7 million, translating to an earnings per share of -$1.82. The gross profit and price-to-earnings ratio both stand at zero. As of now, there are no institution ratings suggesting a buy, hold, or sell for this stock.
Within the biotechnology sector of the U.S. OTC market, where Advaxis, Inc. operates, the overall industry growth is at 0.11%. Some related stocks, such as Coeptis Therapeutics Holdings Inc and Apollomics Inc, have seen significant gains. Meanwhile, stocks like Windtree Therapeutics, Inc., Aditxt, Inc., and Inhibikase Therapeutics, Inc. have been actively traded with high turnover rates.
Advaxis, Inc. is profiled as a clinical-stage oncology company focusing on developing therapies for rare and aggressive cancer types, particularly targeting genetically-defined patient groups with their candidate products AL101 and AL102. AL101 is in development as a potent, selective injectable small molecule gamma-secretase inhibitor aimed at treating an aggressive rare T-cell specific leukemia, T-ALL.
